PT1047422E - Utilizacao de histamina para elevar os niveis de histamina no sangue - Google Patents
Utilizacao de histamina para elevar os niveis de histamina no sangueInfo
- Publication number
- PT1047422E PT1047422E PT98957777T PT98957777T PT1047422E PT 1047422 E PT1047422 E PT 1047422E PT 98957777 T PT98957777 T PT 98957777T PT 98957777 T PT98957777 T PT 98957777T PT 1047422 E PT1047422 E PT 1047422E
- Authority
- PT
- Portugal
- Prior art keywords
- histamine
- levels
- methods
- natural killer
- killer cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Electrophonic Musical Instruments (AREA)
- Road Signs Or Road Markings (AREA)
- Ladders (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/969,384 US6071942A (en) | 1996-05-14 | 1997-11-13 | Elevation of circulating blood histamine levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1047422E true PT1047422E (pt) | 2006-05-31 |
Family
ID=25515502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT98957777T PT1047422E (pt) | 1997-11-13 | 1998-11-10 | Utilizacao de histamina para elevar os niveis de histamina no sangue |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6071942A (pt) |
| EP (1) | EP1047422B1 (pt) |
| JP (1) | JP2001522885A (pt) |
| KR (1) | KR20010031979A (pt) |
| CN (1) | CN1128618C (pt) |
| AT (1) | ATE315393T1 (pt) |
| AU (1) | AU760068B2 (pt) |
| CA (1) | CA2310255A1 (pt) |
| DE (1) | DE69833225T2 (pt) |
| DK (1) | DK1047422T3 (pt) |
| ES (1) | ES2256971T3 (pt) |
| HK (1) | HK1035330A1 (pt) |
| IL (1) | IL135872A0 (pt) |
| PT (1) | PT1047422E (pt) |
| WO (1) | WO1999025341A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6242473B1 (en) * | 1999-01-08 | 2001-06-05 | Maxim Pharmaceuticals, Inc. | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| PT1187611E (pt) * | 1999-06-03 | 2004-10-29 | Maxim Pharm Inc | Composicoes oftalmicas de histamina e sua utilizacoes |
| CN1571674A (zh) * | 2001-10-19 | 2005-01-26 | 马克西姆医药公司 | 组胺治疗肝疾病的用途 |
| US20030143195A1 (en) * | 2002-01-30 | 2003-07-31 | Pinsker Judy Senior | Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery |
| AP2007003939A0 (en) * | 2004-09-03 | 2007-04-30 | Prometic Biosciences Inc | Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides |
| WO2014088641A1 (en) * | 2012-12-05 | 2014-06-12 | Biohealthonomics Inc. | Methods for restoration of histamine balance |
| US9023881B2 (en) | 2012-12-05 | 2015-05-05 | Biohealthonomics Inc. | Methods for restoration of histamine balance |
| US10117908B2 (en) | 2013-10-17 | 2018-11-06 | Grant Labs, Inc. | Suppression of cellular transformation and dysplasia by topical application of lefty |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1911429A1 (de) * | 1969-03-06 | 1970-09-24 | Waldhof Zellstoff Fab | Lipophile Puryl-(6)-histaminderivate und Verfahren zu ihrer Herstellung |
| US4849329A (en) * | 1986-05-30 | 1989-07-18 | E. I. Du Pont De Nemours And Company | Process for preparing lymphokine activated killer cells |
| ES2087163T3 (es) * | 1989-09-19 | 1996-07-16 | Syntello Inc | Preparacion antitumoral que comprende intreleucina-2 e histamina, analogo al de las mismas o agonistas de receptor h2. |
| US5135491A (en) * | 1990-11-02 | 1992-08-04 | Baldwin Brian E | Patient controlled infusion apparatus and method |
| WO1993020803A1 (en) * | 1992-04-22 | 1993-10-28 | Molecular Rx, Inc. | Method and composition for the treatment of disorders involving immunological dysfunction |
| SE513429C2 (sv) * | 1992-06-03 | 2000-09-11 | Syntello Inc | Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer |
| US5843979A (en) * | 1993-02-25 | 1998-12-01 | Bristol-Myers Squibb Company | Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity |
| JP3193205B2 (ja) * | 1993-08-09 | 2001-07-30 | 日本臓器製薬株式会社 | 好酸球増多抑制剤 |
| JPH07165582A (ja) * | 1993-12-08 | 1995-06-27 | Seiji Takayama | 免疫抗癌剤の抗癌効果増強剤 |
| US5478211A (en) * | 1994-03-09 | 1995-12-26 | Baxter International Inc. | Ambulatory infusion pump |
| WO1996005289A1 (en) * | 1994-08-08 | 1996-02-22 | Syntello, Inc. | Enhanced activation of natural killer cells using an nk cell activator and a hydrogen peroxide scavenger or inhibitor |
| US5961969A (en) * | 1996-05-14 | 1999-10-05 | Maxim Pharmaceuticals, Inc. | Stable circulating histamine levels |
-
1997
- 1997-11-13 US US08/969,384 patent/US6071942A/en not_active Expired - Lifetime
-
1998
- 1998-11-10 PT PT98957777T patent/PT1047422E/pt unknown
- 1998-11-10 AT AT98957777T patent/ATE315393T1/de not_active IP Right Cessation
- 1998-11-10 DE DE69833225T patent/DE69833225T2/de not_active Expired - Fee Related
- 1998-11-10 JP JP2000520775A patent/JP2001522885A/ja active Pending
- 1998-11-10 EP EP98957777A patent/EP1047422B1/en not_active Expired - Lifetime
- 1998-11-10 ES ES98957777T patent/ES2256971T3/es not_active Expired - Lifetime
- 1998-11-10 CN CN98813051A patent/CN1128618C/zh not_active Expired - Fee Related
- 1998-11-10 IL IL13587298A patent/IL135872A0/xx unknown
- 1998-11-10 WO PCT/US1998/023956 patent/WO1999025341A1/en active IP Right Grant
- 1998-11-10 CA CA002310255A patent/CA2310255A1/en not_active Abandoned
- 1998-11-10 AU AU13955/99A patent/AU760068B2/en not_active Ceased
- 1998-11-10 DK DK98957777T patent/DK1047422T3/da active
- 1998-11-10 KR KR1020007005089A patent/KR20010031979A/ko not_active Application Discontinuation
-
2000
- 2000-03-15 US US09/526,816 patent/US6613788B1/en not_active Expired - Fee Related
-
2001
- 2001-08-28 HK HK01106069A patent/HK1035330A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1047422A1 (en) | 2000-11-02 |
| KR20010031979A (ko) | 2001-04-16 |
| CN1128618C (zh) | 2003-11-26 |
| DE69833225T2 (de) | 2006-08-10 |
| US6071942A (en) | 2000-06-06 |
| ES2256971T3 (es) | 2006-07-16 |
| DK1047422T3 (da) | 2006-04-18 |
| DE69833225D1 (de) | 2006-04-06 |
| US6613788B1 (en) | 2003-09-02 |
| CN1285744A (zh) | 2001-02-28 |
| AU1395599A (en) | 1999-06-07 |
| HK1035330A1 (en) | 2001-11-23 |
| WO1999025341A1 (en) | 1999-05-27 |
| IL135872A0 (en) | 2001-05-20 |
| ATE315393T1 (de) | 2006-02-15 |
| EP1047422B1 (en) | 2006-01-11 |
| JP2001522885A (ja) | 2001-11-20 |
| CA2310255A1 (en) | 1999-05-27 |
| AU760068B2 (en) | 2003-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE153856T1 (de) | Zusammensetzung zur stimulierung des immunsystems | |
| DK0920322T3 (da) | Anvendelser af modificeret autologt blod til behandling af autoimmunitetssygdomme | |
| TR200003635T2 (tr) | Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması. | |
| ES2186714T3 (es) | Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado. | |
| WO1997042968A3 (en) | Administration of histamine for therapeutic purposes | |
| BR9913932A (pt) | Uso de análogos de glp-1 no tratamento de derrame | |
| BR9711447A (pt) | Uso de glp-1 an logos no tratamento de enfarte de mioc rdio | |
| BRPI0317064B8 (pt) | composições compreendendo células dendríticas parcialmente amadurecidas in vitro | |
| TR200002860T2 (tr) | Bir antiviral benzimidazol terkibin yeni kristal formları. | |
| BR9909583A (pt) | Aumento da resposta imune mediado por uma proteìna de fusão anticorpo-citocina por co-administração com inibidor de angiogênese | |
| AR032912A1 (es) | Formulacion farmaceutica | |
| DK0933995T3 (da) | Fremgangsmåde til behandling af endotelskader | |
| MX9400434A (es) | Potenciamiento de temozolomida en celulas de tumores humanos. | |
| MX9603925A (es) | Combinaciones de anticoagulantes y proteinas activas tromboliticamente, y usos de las mismas. | |
| DE60230807D1 (de) | Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha | |
| PT1047422E (pt) | Utilizacao de histamina para elevar os niveis de histamina no sangue | |
| AR025449A1 (es) | Soluciones farmaceuticas de levosimendan | |
| HUP0400548A2 (hu) | Belső szemnyomást csökkentő hatóanyag-kombinációk alkalmazása glaukoma kezelésére szolgáló gyógyszerkészítmények előállítására | |
| WO2000040229A3 (en) | Synergistic tumorcidal response induced by histamine | |
| Garafalo et al. | Histamine release and therapy of severe dermatographism | |
| DK1063981T3 (da) | Anvendelse af selegilin eller desmethylselegilin til behandling af sår, brandsår og dermatologiske skader | |
| AR015956A1 (es) | Composiciones de citoquinas oromucosales y usos de las mismas | |
| EA200000909A1 (ru) | ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА | |
| CY1106702T1 (el) | Χρηση ενος συνδυασμου μιας πουρινης και ενος παραγοντα δοτη μονοξειδιου του αζωτου για την προληψη ή την αγωγη γενετησιων δυσλειτουργιων | |
| WO2003072606A3 (en) | Galectin-8and functional derivatives as binding agents for cd44 glycoproteins and methods of use |